International licensing and geographic expansion in biopharma

← Ideas · Themes

Multiple companies are aggressively expanding international footprints through licensing deals and regulatory filings, including LENZ's new Arrotex license for Australia/New Zealand and Everest Medicines acquisition of Greater China rights, IKT's Phase 3 IMPROVE-PAH study expansion to 26 countries and 43 sites, and AQST's specific filing timelines for Canada and EU regulatory submissions. This trend reflects companies seeking to maximize asset value through geographic diversification and regional partnerships.

Subscribe to this theme (RSS)